Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium Article

cited authors

  • Mehta, MP; Rodrigus, P; Terhaard, CH; Rao, A; Suh, J; Roa, W; Souhami, L; Bezjak, A; Leibenhaut, M; Komaki, R; Schultz, CJ; Timmerman, R; Illidge, T; Meyers, CA; Curran, WJ; Phan, SC; Smith, J; Renschler, MF

fiu authors

publication date

  • November 1, 2001

Digital Object Identifier (DOI)

start page

  • 135

end page

  • 136


  • 51


  • 3